News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s patent application approved and issued in USA

February 20, 2013

PledPharma AB
Company Announcement

PledPharma's patent application approved and issued in USA

Stockholm, 2013-02-20 10:19 CET (GLOBE NEWSWIRE) -- PledPharma today announces
that it has received patent approval for the US market.  This is the first
patent in a series of worldwide applications aiming to achieve exclusive and
broad commercial rights for manufacturing and use of PLED compounds, including
among others PledOx™ (calmangafodipir). PLED-compounds protect against serious
side effects of chemotherapy drugs during cancer treatment. 

-         “This means a significant competitive advantage for PledPharma and
its brands, says Jacques Näsström, CEO of PledPharma”. 

This particular patent "Compounds for Use in the Treatment of Cancer" covers,
as the title reveals, use of PLED compounds in cancer treatment. 

-          “This is an important milestone for PledPharma, says Jan Olof G.
Karlsson, responsible for patents and one of the founders of PledPharma. To
achieve patent approval takes time and differs between various countries and
regions (for more details see PledPharma’s website). In case of the present
patent, the first application was filed already in December 2007 and is at
present a matter of examination and prosecutions in the various countries and
regions. PledPharma has thereafter filed several other applications.  As US is
the most important market for drugs as those developed by PledPharma, it is
indeed satisfying that we have achieved approval in the US as the first
country, says Jan Olof.” 

For further information please contact:

Jacques Näsström, CEO, +46 737 130 979,

Jan Olof G. Karlsson, Senior Scientist, +46 733 304 624, 

About PledPharma

PledPharma is a Swedish specialty pharma company that develops PledOx™
(calmangafodipir) for prevention of severe chemotherapy-induced side effects in
cancer patients. Due to these side effects optimal treatment cannot be carried
out. The current market for supportive cancer care is some SEK 72 billion.
PledOx protects normal cells against oxidative stress. It belongs to a group of
compounds named lowMEM (low Molecular Enzyme Mimetics), and mimics the enzyme
Manganese SuperOxide Distmutase (MnSOD) – the most important endogenous
cellular protectant against devastating oxidative stress. Oxidative stress is a
condition caused by harmful oxygen/nitrogen molecules, e.g., as a result of
chemotherapy treatment. The company is also evaluating opportunities of using
PLED substances in other diseases. PledPharma (STO:PLED) is listed on NASDAQ
OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For
further information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10